1-20 of 55
Katja C. Weisel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients

Elias K. Mai, Andrea Manubens, Mattia D'Agostino, David A. Cairns, Alessandra Larocca, Juan José Lahuerta Palacios, Ruth Wester, Uta Bertsch, Anders Waage, Elena Zamagni, María-Victoria Mateos, Daniele Dall'Olio, Niels W.C.J. van de Donk, Graham Jackson, Serena Rocchi, Hans Salwender, Joan Bladé, Bronno van der Holt, Gastone Castellani, Katja C. Weisel, Francesca Gay, Sonja Zweegman, Michele Cavo, Jesus Maria Hernandez Rivas, Benedetto Bruno, Gordon Cook, Martin F Kaiser, Hartmut Goldschmidt, Mario Boccadoro, Jesús F. San-Miguel, Pieter Sonneveld
Journal: Blood
Blood (2024) 144 (Supplement 1): 898.
https://doi.org/10.1182/blood-2024-193310
Published: 2024
Journal Articles

Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma

Kai Rejeski, Doris K. Hansen, David M. Cordas Dos Santos, Andre De Menezes Silva Corraes, Omar Castaneda, Christen M Dillard, Winfried Alsdorf, Jan H. Frenking, Anna Purcarea, Saurabh Chhabra, Ciara Louise Freeman, Mirco Julian Friedrich, Mahmoud R. Gaballa, Rebecca Gonzalez, Syed Hamza Bin Waqar, Yi Lisa Hwa, Michael D. Jain, Ricardo D. Parrondo, Oren Pasvolsky, Wajma Shahbaz, Roni Shouval, Genevieve Spiess, Haily Stephens, Sebastian Theurich, Florian Bassermann, Judith S. Hecker, Marc S. Raab, Katja C. Weisel, Frederick L. Locke, Marion Subklewe, Krina K. Patel, Yi Lin
Journal: Blood
Blood (2024) 144 (Supplement 1): 895.
https://doi.org/10.1182/blood-2024-208376
Published: 2024
Journal Articles

Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

Hartmut Goldschmidt, Uta Bertsch, Ema Pozek, Axel Benner, Roland Fenk, Britta Besemer, Christine Hanoun, Roland Schroers, Ivana von Metzler, Mathias Hänel, Christoph Mann, Lisa Leypoldt, Bernhard Heilmeier, Stefanie Huhn, Sabine Vogel, Michael Hundemer, Christof Scheid, Igor Wolfgang Blau, Steffen Luntz, Tobias A.W. Holderried, Karolin Trautmann-Grill, Deniz Gezer, Maika Klaiber-Hakimi, Martin Mueller, Evgenii Shumilov, Wolfgang Knauf, Christian Sebastian Michel, Thomas Geer, Hendrik Riesenberg, Christoph Lutz, Marc-Steffen Raab, Martin Hoffmann, Katja C. Weisel, Hans Salwender, Elias K. Mai
Journal: Blood
Blood (2024) 144 (Supplement 1): 769.
https://doi.org/10.1182/blood-2024-193308
Published: 2024
Journal Articles

Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Subgroup Analysis of the GMMG HD6 Phase III Trial

Maximilian Merz, Ema Pozek, Kaya Miah, Uta Bertsch, Britta Besemer, Mathias Hänel, Julia Krzykalla, Roland Fenk, Jana Schlenzka, Markus Munder, Christine Hanoun, Christoph Mann, Niels Weinhold, Christof Scheid, Roland Schroers, Igor Wolfgang Blau, Stefanie Huhn, Dirk Hose, Anna Jauch, Christina Kunz, Ivana von Metzler, Aneta Schieferdecker, Jörg Thomalla, Peter Reimer, Rolf Mahlberg, Ullrich Graeven, Stephan Kremers, Uwe Martens, Manfred Hensel, Axel Benner, Andrea Seidel-Glätzer, Katja C. Weisel, Marc S. Raab, Hans Salwender, Hartmut Goldschmidt, Elias K. Mai
Journal: Blood
Blood (2024) 144 (Supplement 1): 84.
https://doi.org/10.1182/blood-2024-201972
Published: 2024
Journal Articles

Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis

Saad Z. Usmani, Michal Mielnik, Mamta Garg, Irwindeep Sandhu, Al-Ola Abdallah, Youngil Koh, Albert Oriol, Hang Quach, Katja C. Weisel, Aranzazu Alonso Alonso, Enrique M Ocio, Wojciech Janowski, Chang-Ki Min, Karthik Ramasamy, Ricarda García Sánchez, Paula Rodríguez-Otero, Chris Brawley, Jacqueline L Egger, Morrys C Kaisermann, Marek Hus
Journal: Blood
Blood (2024) 144 (Supplement 1): 497.
https://doi.org/10.1182/blood-2024-198669
Published: 2024
Journal Articles

ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study

Cesar Rodriguez, Michal Mielnik, Dickran Kazandjian, Wojt Janowski, Michael S.Y. Low, Matthew Pianko, Junichiro Yuda, Carrie Van Der Weyden, Larry D Anderson, Jr., Rahul Banerjee, Laura Rosinol Dachs, Claudio Cerchione, Malin Hultcrantz, Anita D'Souza, Amandeep Godara, Ariel Grajales-Cruz, Ziyi Jin, Akshanth R Polepally, Aarif Ahsan, Shane Lee, Kristin D'Amico, Orlando Bueno, Chetasi Talati, Anders Erik Svensson, Leanne Fleming, Katja C. Weisel, Marek Hus, Peter M. Voorhees
Journal: Blood
Blood (2024) 144 (Supplement 1): 496.
https://doi.org/10.1182/blood-2024-205083
Published: 2024
Journal Articles

Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial

Marc S. Raab, Niels Weinhold, K. Martin Kortüm, Jan Krönke, Lilli Podola, Uta Bertsch, Jan H. Frenking, Julia Mersi, Stefanie Huhn, Michael Hundemer, Gunhild Mechtersheimer, Roland Fenk, Katja C. Weisel, Natalie Schub, Florian Bassermann, Monika Engelhardt, Raphael Teipel, Mathias Hänel, Hans Salwender, Bas D Koster, Elena Ershova, Caline Sakabedoyan, Isobel Barrott, Agnes Balogh, Sanjay Vara, Tobias Kampfenkel, Hartmut Goldschmidt, Hermann Einsele, Leo Rasche
Journal: Blood
Blood (2024) 144 (Supplement 1): 493.
https://doi.org/10.1182/blood-2024-206003
Published: 2024
Journal Articles

Comparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis

Shaji Kumar, Sundar Jagannath, Katja C. Weisel, Laura Rosiñol Dachs, Meletios-Athanasios Dimopoulos, David S. Siegel, Jorge Monge, Xavier Leleu, Juan Du, Javier de la Rubia, Jae Hoon Lee, María-Victoria Mateos, Borja Puertas Martínez, Alessandro Gozzetti, Dominik Dytfeld, Enrique M. Ocio, Joan Bladé, Shuji Ozaki, Meral Beksac, Fernando Escalante, Madhu Nagaraj, Rafla Hassan, Paul Spin, Nicolle Bonar, Mostafa Shokoohi, Muhaimen Siddiqui, Di Wang, Kevin Hou, Jeannette Green, Olivier Humblet, Alexander Breskin, James Harnett, Wenzhen Ge, Rachel E. Sobel, Jessica J. Jalbert, Glenn S. Kroog, Karen Rodriguez Lorenc, Qiufei Ma, Christian Hampp, Brian G.M. Durie
Journal: Blood
Blood (2024) 144 (Supplement 1): 7012.
https://doi.org/10.1182/blood-2024-200679
Published: 2024
Journal Articles

Comparative Effectiveness of Ciltacabtagene Autoleucel from the Cartitude-4 Trial Vs Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma - an Updated Overall Survival Analysis

Cyrille Touzeau, Brea Lipe, Abdullah Mohammad Khan, Binod Dhakal, Sandhya Nair, Jianming He, João Mendes, Seina Lee, Carolina Lonardi, Ana Slaughter, Nikoletta Lendvai, Jordan M. Schecter, Diana Chen, Man Zhao, Tzu-min Yeh, Xavier Leleu, Noemi Puig, Dominik Dytfeld, Elena Zamagni, Katja C. Weisel, Lionel Karlin, Michel Delforge, Paolo Corradini, Roberto Mina, Wilfried Roeloffzen, Surbhi Sidana
Journal: Blood
Blood (2024) 144 (Supplement 1): 7089.
https://doi.org/10.1182/blood-2024-205383
Published: 2024
Journal Articles

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Isatuximab, Carfilzomib and Dexamethasone in the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Roberto Mina, Paolo Corradini, Michele Cavo, Jesús F. San-Miguel, Leyla O. Shune, Abdullah Mohammad Khan, Surbhi Sidana, Xavier Leleu, Salomon Manier, Brea Lipe, Katja C. Weisel, Suzy van Sanden, Joris Diels, João Mendes, Seina Lee, Sandra Van Hoorenbeeck, Adrián Pons, Ana Slaughter, Nina Benachour, Carolina Lonardi, Arnab Ghosh, Nitin Patel, Erika Florendo, Joaquín Martínez-Lopez
Journal: Blood
Blood (2024) 144 (Supplement 1): 7088.
https://doi.org/10.1182/blood-2024-205189
Published: 2024
Journal Articles

Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites

Shaji Kumar, Sundar Jagannath, Katja C. Weisel, Laura Rosiñol Dachs, Meletios-Athanasios Dimopoulos, David S. Siegel, Jorge Monge, Xavier Leleu, Juan Du, Javier de la Rubia, Jae Hoon Lee, María-Victoria Mateos, Alessandro Gozzetti, Dominik Dytfeld, Enrique M. Ocio, Joan Bladé, Shuji Ozaki, Madhu Nagaraj, Rafla Hassan, Jeannette Green, Glenn S. Kroog, Karen Rodriguez Lorenc, Christian Hampp, Qiufei Ma, Brian G.M. Durie
Journal: Blood
Blood (2024) 144 (Supplement 1): 7039.
https://doi.org/10.1182/blood-2024-210376
Published: 2024
Journal Articles

Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement

Maximilian J. Steinhardt, Christoph Schaefers, Lisa Leypoldt, Marie Harzer, Xiang Zhou, Christine Riedhammer, Abdulaziz Kamili, Ricardo Kosch, Jule Arztenroth, Maximilian Al-Bazaz, Winfried Alsdorf, Max S. Topp, Johannes Duell, Julia Mersi, Johannes Waldschmidt, Carsten Bokemeyer, Hermann Einsele, K. Martin Kortüm, Katja C. Weisel, Leo Rasche
Journal: Blood
Blood (2024) 144 (Supplement 1): 3792.4.
https://doi.org/10.1182/blood-2024-206735
Published: 2024
Journal Articles

Clonal Evolution of Lymphoid Malignancies Following the Mutagenic Impact of Radiotherapy

Benjamin Diamond, Dhanvantri Chahar, Michael D. Jain, Alexandra Maria Poos, Michael Durante, Bachisio Ziccheddu, Marcella Kaddoura, Marios Papadimitriou, Kylee H Maclachlan, Tomas Jelinek, Faith E Davies, Nicholas B Figura, Gareth Morgan, Elias K. Mai, Hartmut Goldschmidt, Katja C. Weisel, Roland Fenk, Saad Z. Usmani, Ola Landgren, Frederick Locke, Marc S. Raab, Jonathan H. Schatz, Niels Weinhold, Francesco Maura
Journal: Blood
Blood (2024) 144 (Supplement 1): 1607.
https://doi.org/10.1182/blood-2024-200927
Published: 2024
Journal Articles

Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial

Noffar Bar, Roberto Mina, Anne K. Mylin, Hisayuki Yokoyama, Hila Magen, Winfried Alsdorf, Monique C. Minnema, Leyla O. Shune, Iris Isufi, Simon J Harrison, Urvi A. Shah, André De Champlain, Katharine S. Gries, Diana Chen, Quanlin Li, Tzu-Min Yeh, Ana Slaughter, Carolina Lonardi, Nina Benachour, Arnab Ghosh, William Deraedt, Martin Vogel, Nikoletta Lendvai, Nitin Patel, Octavio Costa Filho, Erika Florendo, Lionel Karlin, Katja C. Weisel
Journal: Blood
Blood (2024) 144 (Supplement 1): 2002.
https://doi.org/10.1182/blood-2024-209232
Published: 2024
Journal Articles

Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial

Elias K. Mai, Hans Salwender, Michael Hundemer, Uta Bertsch, Ema Pozek, Axel Benner, Roland Fenk, Britta Besemer, Christine Hanoun, Roland Schroers, Ivana von Metzler, Mathias Hänel, Christoph Mann, Lisa Leypoldt, Bernhard Heilmeier, Stefanie Huhn, Sabine Vogel, Christof Scheid, Igor Wolfgang Blau, Steffen Luntz, Niels Weinhold, Tobias A.W. Holderried, Karolin Trautmann-Grill, Deniz Gezer, Maika Klaiber-Hakimi, Martin Mueller, Evgenii Shumilov, Wolfgang Knauf, Christian Sebastian Michel, Thomas Geer, Hendrik Riesenberg, Christoph Lutz, Marc S. Raab, Martin Hoffmann, Katja C. Weisel, Hartmut Goldschmidt
Journal: Blood
Blood (2024) 144 (Supplement 1): 364.
https://doi.org/10.1182/blood-2024-194768
Published: 2024
Journal Articles

Quality of Life in the Multicenter, Randomized, Phase 3 GMMG-HD6 Trial Applying Elotuzumab, Lenalidomide, Bortezomib and Dexaemethason in Patients with Newly-Diagnosed Multiple Myeloma

Anna Fleischer, Elias K. Mai, Kaya Miah, Uta Bertsch, Britta Besemer, Mathias Hänel, Roland Fenk, Markus Munder, Christine Hanoun, Igor Wolfgang Blau, Christoph Mann, Christof Scheid, Roland Schroers, Ivana von Metzler, Aneta Schieferdecker, Jörg Thomalla, Peter Reimer, Rolf Mahlberg, Ullrich Graeven, Stephan Kremers, Uwe Martens, Christian Kunz, Manfred Hensel, Marc S. Raab, Katja C. Weisel, Hans Salwender, Imad Maatouk, Hartmut Goldschmidt
Journal: Blood
Blood (2024) 144 (Supplement 1): 1963.
https://doi.org/10.1182/blood-2024-205230
Published: 2024
Journal Articles

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

Anthony M. Cirrincione, Alexandra M. Poos, Bachisio Ziccheddu, Marcella Kaddoura, Marc-Andrea Bärtsch, Kylee Maclachlan, Monika Chojnacka, Benjamin Diamond, Lukas John, Philipp Reichert, Stefanie Huhn, Patrick Blaney, Dylan Gagler, Karsten Rippe, Yanming Zhang, Ahmet Dogan, Alexander M. Lesokhin, Faith Davies, Hartmut Goldschmidt, Roland Fenk, Katja C. Weisel, Elias K. Mai, Neha Korde, Gareth J. Morgan, Saad Usmani, Ola Landgren, Marc S. Raab, Niels Weinhold, Francesco Maura
Journal: Blood
Blood (2024) 144 (7): 771–783.
https://doi.org/10.1182/blood.2024024299
Published: 2024
Includes: Supplemental data
Journal Articles

Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimismm Trial By Patient Age and Prior Stem Cell Transplant

Meletios A. Dimopoulos, MD, Katja C. Weisel, MD, Philippe Moreau, MD, Larry D. Anderson, MD PhD, Darrell J White, MD, Jesús San-Miguel, Pieter Sonneveld, Monika Engelhardt, MD, Matthew Jenner, MBBS, MRCP, FRCPath, Alessandro Corso, Jan Dürig, Michel Pavic, MD, Morten Salomo, MD PhD, Eva Casal, Ruiyun Jiang, Shankar Srinivasan, PhD MBA, Tuong Vi Nguyen, Tsvetan Biyukov, MD, Teresa Peluso, Paul G. Richardson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3120.
https://doi.org/10.1182/blood-2019-124349
Published: 2019
Journal Articles

Characterization of Relapse and Second-Line Therapy in Lenalidomide-Refractory, Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Subanalysis of the Phase 3 First Trial

Salmon Manier, Meletios A. Dimopoulos, MD, Cyrille Hulin, MD, Xavier Leleu, MD PhD, Michel Delforge, Katja C. Weisel, MD, Ruiyun Jiang, Shankar Srinivasan, PhD MBA, Bruno Costa, Suzanne Robinson, Thierry Facon, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3122.
https://doi.org/10.1182/blood-2019-124557
Published: 2019
Journal Articles

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor

Katja C. Weisel, MD, Pieter Sonneveld, Maria-Victoria Mateos, Vania T.M. Hungria, MD PhD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Jane Estell, FRACP, Wolney G Barreto, Paolo Corradini, Chang-Ki Min, MD PhD, Eva Medvedova, MD, Maria Krevvata, PhD, Sonali Trivedi, Xiang Qin, Huiling Pei, PhD, Jon Ukropec, PhD, Rachel Kobos, MD, Ming Qi, MD PhD, Ajay K Nooka, MDMPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 3192.
https://doi.org/10.1182/blood-2019-123527
Published: 2019